280 related articles for article (PubMed ID: 22341852)
1. Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome.
Abdulahad WH; Kroese FG; Vissink A; Bootsma H
J Autoimmun; 2012 Aug; 39(1-2):103-11. PubMed ID: 22341852
[TBL] [Abstract][Full Text] [Related]
2. B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment.
Cornec D; Devauchelle-Pensec V; Tobón GJ; Pers JO; Jousse-Joulin S; Saraux A
J Autoimmun; 2012 Sep; 39(3):161-7. PubMed ID: 22749831
[TBL] [Abstract][Full Text] [Related]
3. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
Hamza N; Bootsma H; Yuvaraj S; Spijkervet FK; Haacke EA; Pollard RP; Visser A; Vissink A; Kallenberg CG; Kroese FG; Bos NA
Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459
[TBL] [Abstract][Full Text] [Related]
4. B-cell populations and sub-populations in Sjögren's syndrome.
Hamza N; Bos NA; Kallenberg CG
Presse Med; 2012 Sep; 41(9 Pt 2):e475-83. PubMed ID: 22841377
[TBL] [Abstract][Full Text] [Related]
5. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome.
Lavie F; Miceli-Richard C; Quillard J; Roux S; Leclerc P; Mariette X
J Pathol; 2004 Apr; 202(4):496-502. PubMed ID: 15095277
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential for B-cell modulation in Sjögren's syndrome.
Mariette X
Rheum Dis Clin North Am; 2008 Nov; 34(4):1025-33, x. PubMed ID: 18984420
[TBL] [Abstract][Full Text] [Related]
7. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome.
Lavie F; Miceli-Richard C; Ittah M; Sellam J; Gottenberg JE; Mariette X
Scand J Immunol; 2008 Feb; 67(2):185-92. PubMed ID: 18201372
[TBL] [Abstract][Full Text] [Related]
8. BAFF overexpression increases lymphocytic infiltration in Sjögren's target tissue, but only inefficiently promotes ectopic B-cell differentiation.
Ding J; Zhang W; Haskett S; Pellerin A; Xu S; Petersen B; Jandreski L; Hamann S; Reynolds TL; Zheng TS; Mingueneau M
Clin Immunol; 2016 Aug; 169():69-79. PubMed ID: 27352977
[TBL] [Abstract][Full Text] [Related]
9. B cell-targeted therapies in Sjögren's syndrome.
Tobón GJ; Pers JO; Youinou P; Saraux A
Autoimmun Rev; 2010 Feb; 9(4):224-8. PubMed ID: 19671451
[TBL] [Abstract][Full Text] [Related]
10. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome.
Ittah M; Miceli-Richard C; Eric Gottenberg J; Lavie F; Lazure T; Ba N; Sellam J; Lepajolec C; Mariette X
Arthritis Res Ther; 2006; 8(2):R51. PubMed ID: 16507175
[TBL] [Abstract][Full Text] [Related]
11. Th17 cells in primary Sjögren's syndrome: Pathogenicity and plasticity.
Verstappen GM; Corneth OBJ; Bootsma H; Kroese FGM
J Autoimmun; 2018 Feb; 87():16-25. PubMed ID: 29191572
[TBL] [Abstract][Full Text] [Related]
12. B-cell tolerance breakdown in Sjögren's syndrome: focus on BAFF.
Varin MM; Le Pottier L; Youinou P; Saulep D; Mackay F; Pers JO
Autoimmun Rev; 2010 Jul; 9(9):604-8. PubMed ID: 20457281
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiological cytokine network in primary Sjögren's syndrome.
Pers JO; Lahiri A; Tobón GJ; Youinou P
Presse Med; 2012 Sep; 41(9 Pt 2):e467-74. PubMed ID: 22836197
[TBL] [Abstract][Full Text] [Related]
14. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
[TBL] [Abstract][Full Text] [Related]
15. The future of B cell-targeted therapies in Sjögren's syndrome.
Cornec D; Saraux A; Devauchelle-Pensec V; Clodic C; Pers JO
Immunotherapy; 2013 Jun; 5(6):639-46. PubMed ID: 23725286
[TBL] [Abstract][Full Text] [Related]
16. Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome.
Daridon C; Pers JO; Devauchelle V; Martins-Carvalho C; Hutin P; Pennec YL; Saraux A; Youinou P
Arthritis Rheum; 2006 Jul; 54(7):2280-8. PubMed ID: 16802367
[TBL] [Abstract][Full Text] [Related]
17. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus.
Sellam J; Miceli-Richard C; Gottenberg JE; Ittah M; Lavie F; Lacabaratz C; Gestermann N; Proust A; Lambotte O; Mariette X
Ann Rheum Dis; 2007 Jun; 66(6):790-7. PubMed ID: 17185325
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Potential of Anti-Interferon α Vaccination on SjS-Related Features in the MRL/lpr Autoimmune Mouse Model.
Killian M; Colaone F; Haumont P; Nicco C; Cerles O; Chouzenoux S; Cathébras P; Rochereau N; Chanut B; Thomas M; Laroche N; Forest F; Grouard-Vogel G; Batteux F; Paul S
Front Immunol; 2021; 12():666134. PubMed ID: 34867938
[TBL] [Abstract][Full Text] [Related]
19. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P
Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
[TBL] [Abstract][Full Text] [Related]
20. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome.
Pollard RP; Abdulahad WH; Bootsma H; Meiners PM; Spijkervet FK; Huitema MG; Burgerhof JG; Vissink A; Kroese FG
Ann Rheum Dis; 2013 Dec; 72(12):2048-50. PubMed ID: 23864239
[No Abstract] [Full Text] [Related]
[Next] [New Search]
